Rubicon Research’s Explosive 76% Growth: Inside The US-Focused IPO Story | IPO Central | ET Now #ETNOW
Rubicon Research’s Explosive 76% Growth: Inside The US-Focused IPO Story | IPO Central | ET Now
Rubicon, India’s fastest-growing pharma formulations firm (76% CAGR FY23-25), focuses on US generics and brands via R&D in India/North America. IPO raises ₹500Cr for debt repayment and inorganic acquisitions targeting US branded synergies. Tariffs minimally impact generics; 17 FDA approvals pending, expecting 10-15 annually.
#rubiconresearch #ipohype #pharmagrowth #usgenerics #fdaapprovals #tarifftalk #indiapharma #brandeddrugs #acquisitionstrategy #r&dinnovation #etnow
control your money with economic times now.
YouTube Channel – https://www.youtube.com/@ETNow
Subscribe To ET Now For Latest Updates On Stocks Market News , Business News, Company News, IPO & More | https://bit.ly/SubscribeToETNow
Subscribe Now To Our Network Channels :-
ET Now Swadesh: https://www.youtube.com/etnowswadesh
Times Now: http://goo.gl/U9ibPb
Social Media Links :-
Twitter – http://goo.gl/hA0vDt
Facebook – http://goo.gl/5Lr4mC
Website – https://ift.tt/gjkAO9M
Follow us on Google News for latest updates
ET Now: https://ift.tt/LZXVvNH
Times Now Navbharat: https://bit.ly/3zDaKJo
Times Now : https://bit.ly/3CyrrYg
Zoom: https://bit.ly/3CEK0dv
Thank you for your support in keeping this website running.💛
View on “Tokyo Trend News”
コメントを送信